Blood

Journal

Publication Venue For

  • A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia.  132:1855-1855. 2018
  • Ineffective erythropoiesis of TET2 deficiency.  132:2320-2321. 2018
  • FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML).  128:1681-1681. 2016
  • Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent..  128:1845-1853. 2016
  • Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome..  127:948-951. 2016
  • Emerging EPO and EPO receptor regulators and signal transducers..  125:3536-3541. 2015
  • The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma..  125:3118-3127. 2015
  • Erythroid mRNA processing: a "splice of life"..  124:474-475. 2014
  • GLI2 Transcription Factor Modulates CD40 Ligand Expression In Bone Marrow Stromal Cells.  122:4271-4271. 2013
  • Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins.  120:399-399. 2012
  • Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2..  119:5522-5531. 2012
  • Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity..  118:5540-5549. 2011
  • The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors..  117:3421-3429. 2011
  • During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool..  116:5334-5346. 2010
  • GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment.  116:613-613. 2010
  • Micro-mismanaging sickle cell stress..  116:4040-4042. 2010
  • Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells..  114:1905-1905. 2009
  • Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenström Macroglobulinemia..  114:1691-1691. 2009
  • Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells..  114:2936-2944. 2009
  • CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools..  113:4955-4962. 2009
  • Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3..  112:5095-5102. 2008
  • Attenuation of EPO-dependent erythroblast formation by death-associated protein kinase-2..  112:886-890. 2008
  • EPO receptor circuits for primary erythroblast survival..  111:5390-5399. 2008
  • Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells..  110:2953-2953. 2007
  • EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts..  110:2361-2370. 2007
  • Erythropoietin modulation of podocalyxin and a proposed erythroblast niche..  110:509-518. 2007
  • Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma..  108:3450-3450. 2006
  • Lyn kinase promotes erythroblast expansion and late-stage development..  108:1524-1532. 2006
  • Selective activation of TACI by syndecan-2..  107:3235-3242. 2006
  • B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia..  107:2882-2888. 2006
  • Core erythropoietin receptor signals for late erythroblast development..  107:2662-2672. 2006
  • Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation..  106:3191-3199. 2005
  • Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells..  102:3147-3153. 2003
  • Erythropoietin receptor-dependent erythroid colony-forming unit development: capacities of Y343 and phosphotyrosine-null receptor forms..  99:898-904. 2002
  • mDYRK3 kinase is expressed selectively in late erythroid progenitor cells and attenuates colony-forming unit-erythroid development..  97:901-910. 2001
  • A minimal cytoplasmic subdomain of the erythropoietin receptor mediates erythroid and megakaryocytic cell development..  94:3381-3387. 1999
  • Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization..  92:1104-1118. 1998
  • Tumor cell cytotoxicity of a novel metal chelator..  92:1384-1389. 1998
  • Mechanisms of stem cell factor and erythropoietin proliferative co-signaling in FDC2-ER cells..  90:3533-3545. 1997
  • Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells..  90:2175-2187. 1997
  • Functional interaction of GATA1 with erythroid Krüppel-like factor and Sp1 at defined erythroid promoters..  87:1793-1801. 1996
  • Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells..  86:557-571. 1995
  • Steel factor affects SCL expression during normal erythroid differentiation..  84:2971-2976. 1994
  • Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain..  82:3530-3538. 1993
  • BIOTINYLATED ERYTHROPOIETIN - REPLY.  74:2772-2773. 1989
  • Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligand..  74:952-958. 1989
  • High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector..  74:652-657. 1989
  • Novel EPO/EPOR/JAK2 targets and signal transduction pathways revealed by phospho-PTM proteomic profiling
  • "C1ORF150", a Novel Mediator of EPO/EPOR/JAK2 Dependent Human Erythroid Progenitor Cell Formation 2016
  • EPO Modulation of Thioredoxin Interacting Protein (TXNIP), and Key Roles for TXNIP during EPO-Dependent Human Erythroid Progenitor Cell Growth and Development 2015
  • Podocalyxin Negatively Regulates Stress Myelopoiesis, Directly Binds Rap-1A and Modulates Its G-CSF-Induced Activity 2015
  • A Novel Mechanism of GLI2 Mediated Regulation of IgM Secretion in Waldenstrom Macroglobulinemia 2014
  • Discovery of Novel EPO/EPOR/JAK2 Targets and Signal Transduction Factors Via Proteomic-Based Interrogations of Post-Translational Motif Modifications 2014
  • GLI Transcription Factors Modulate IgM Secretion In Waldenstrom Macroglobulinemia 2013
  • Ligand-Regulated and Developmental Stage-Specific Expression Of The EPO Receptor During Human Erythroid Progenitor Cell Formation 2013
  • The Human Platelet Glycome and Its Variations Among Healthy Volunteers and Storage 2013
  • The Transcription Factor GLI3 Is a Novel Candidate Effector Of Toll-Like Receptor 4 (TLR4) Signaling In Monocytes 2013
  • Trib2 Pseudokinase Marks Early CMP Progenitors, and Promotes Granulocytic Plus Erythroid Progenitor Cell Formation 2013
  • Erythropoietin-Directed Erythropoiesis Depends Upon Serpin Inhibition of Erythroblast Lysosomal Cathepsins 2012
  • Hematopoietic Lineage Selective Roles for Trib Pseudokinases Post Bone Marrow Transplantation 2012
  • The Erythropoiesis Stimulating Agent Omontys/Peginesatide up-Modulates Erythroid Progenitor Formation, and Cell Surface Erythropoietin Receptor Levels 2012
  • "RHEX-26", a Novel EPO/EPOR-Regulated Mediator of Human Erythroid Progenitor Cell Expansion 2011
  • Dynamic Erythropoietin Receptor Trafficking Within Cell Surface, and Intracellular Pools 2010
  • Epo Engages a Tnfr-13c Pathway to Advance for Primary Bone Marrow (Pro)Erythroblast Development 2010
  • GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment 2010
  • BMP Signaling Is Crucial for Regulation Vascular Progenitor Development in Human Embryonic Stem Cells. 2009
  • Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstrom Macroglobulinemia. 2009
  • Spry1 Plays Selective Hematopoietic Roles as An Erythropoietin - Modulated Positive Regulator of Erythropoiesis 2009
  • TRIB3 Pseudokinase Is Induced Via An EPO/EPOR/STAT5 Pathway, Markedly up-Modulated in Late-Stage Erythroblasts, and Plays An Essential Non-Redundant Role During Stress Erythropoiesis 2009
  • Comprehensive Analysis of the Waldenstrom Macroglobulinemia "Cytokine Milieu" Reveals a Novel Role of Rantes Signaling in the Regulation of Immunoglobulin Production 2008
  • Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 2008
  • Non-Redundant Roles for an Epo/EpoR/STAT5 Regulated Intracellular Serpin, Serpina-3G, during Epo- and Anemia- Induced Erythropoiesis 2008
  • miRNA Analysis Identifies a Unique Expression in Waldenstrom Macroglobulinemia B Cells and Plasma Cells 2008
  • GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia 2007
  • Multiplex analysis of serum cytokine levels in Waldenstrom macroglobulinemia patients 2007
  • Epo modulation of cell cycle regulatory genes via PY343/STAT5 and PI3K pathways in primary erythroblasts. 2006
  • Epo receptor circuits to Irs2, Foxo3a, Trb3 and Bim 1 expression, and erythroblast survival. 2006
  • Erythropoietin modulation of podocalyxin within an erythroblast niche. 2006
  • Preferential inhibition of malignant cell growth by CDDO in Waldenstrom macroglobulinemia. 2006
  • Transgenic GATA1ie3.9int - DAPK2 mice exhibit low-grade anemia, deficient stress erythropoiesis, and compromised erythroblast survival. 2006
  • Role of B-lymphocyte stimulator (BLyS) in Waldenstrom's macroglobulinemia. 2005
  • Core epo receptor signaling circuits in adult bone marrow-derived primary pro-erythroblasts. 2004
  • Death associated protein kinase 2 (DAPK2): A novel Epo-modulated apoptotic regulator of late erythropoiesis. 2004
  • Kit PY567-directed signals are important for efficient erythroid progenitor cell proliferation and survival, and are attenuated by Kit PY569. 2004
  • Lyn kinase supports primary erythroid progenitor cell development. 2004
  • Assisting mechanisms during PY-null Epo receptor allele dependent steady-state erythropoiesis. 2003
  • Stress erythropoiesis is not efficiently supported by a minimal Epo receptor phosphotyrosine-null allele. 2003
  • DYRK3 activation mechanisms, PKA/CREB engagement and modulation of progenitor cell survival. 2002
  • Dynamics of pro-erythroblasts growth and differentiation revealed through gene profiling. 2002
  • Roles for Epo receptor Y343 (and Stat5) in Kit synergy. 2002
  • Purification of developmentally staged erythroid progenitor cells in numbers sufficient for gene profiling of CFUe development. 2001
  • SCF/Epo synergy in primary CFUe is mediated efficiently by Epo receptor phosphotyrosine-independent mechanisms. 2001
  • An optimized primary cell system for investigators of regulated erythropoiesis: Developmentally synchronized splenic erythroid progenitor cells from thiamphenicol-treated transgenic mice. 2000
  • Erythroid-restricted expression and repressive role for mDYRK3 dual-specificity kinase in CFUe development. 2000
  • Critical, concentrations of FOG are required for alpha IIb gene activation via both GATA-1-dependent, and independent mechanisms. 1999
  • SCF synergizes with Epo via Epo receptor (p)y-dependent and -independent routes, selectively enhances Epo/Jak2/STAT5-dependent bclx & bcl2 gene transcription, and is the primary activator of Erks. 1999
  • Regulation of GATA-1 gene expression: Roles for FOG, GATA-1, EPO, and novel activating and repressing cis-domains. 1998
  • Subtraction cloning and initial characterization of novel EPO-response genes. 1998
  • Co-expression of GATA-1 and the Epo receptor in myeloid FDCW2 cells prolongs the cell cycle at G(1), attenuates proliferation and activates endogenous erythroid gene expression. 1997
  • Pim1 inhibits cell death: Induction of Pim1 and Pim2 transcription via a minimal Epo receptor form and modulation of apoptosis upon the deregulated expression of Pim1. 1997
  • Epo-induced hemoglobinization of SKT6 cells is blocked by a dominant-negative form of STAT5. 1996
  • EPO signaling via minimal mitogenic receptor forms, and via STAT factors in differentiating erythroid SKT6-40 cells. 1995
  • ROLES FOR JAK2 KINASE IN EPO-INDUCED MITOGENESIS, INHIBITED APOPTOSIS, AND ERYTHROID-DIFFERENTIATION 1994
  • ASSOCIATION OF P85/P13-K WITH THE EPO RECEPTOR WITHIN THE EXTENDED BOX-2 DOMAIN, AND POSSIBLE ROLES FOR JAK-2 IN P13-K ACTIVATION 1993
  • Has Subject Area

    International Standard Serial Number (issn)

  • 0006-4971
  • Electronic International Standard Serial Number (eissn)

  • 1528-0020